- Home
- / Calliditas Therapeutics
Calliditas Therapeutics
Stock Price
KR208
2024-10-10
Market Capitalization
KR11.2 B
2024-10-10
Revenue
KR1.2 B
FY, 2023
Calliditas Therapeutics Summary
Company Summary
- Overview
- Calliditas Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments in orphan indications. It offers Nefecon, an oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy.
- Type
- Public
- Status
- Active
- Founded
- 2004
- HQ
- Stockholm, SE | view all locations
- Website
- https://www.calliditas.se/
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Molly Henderson, Non-Executive Director
Richard Philipson, Chief Medical Officer
Elmar Schnee, Chairman
LocationsView all
7 locations detected
Stockholm, Stockholms län HQ
Sweden
Kungsbron 1, d5
Hoboken, NJ
United States
5 Marine View Plaza
New York, NY
United States
330 Madison Ave #23rd
Archamps, Auvergne-Rhône-Alpes
France
218 Avenue Marie Curie, Forum 2 Archamps Technopole
Stockholm, Stockholm County
Sweden
PO Box 70351
Stockholm, Stockholms län
Sweden
Wallingatan 26B
Calliditas Therapeutics Financials
Summary Financials
- Revenue (Q2, 2024)
- kr559.8M
- Gross profit (Q2, 2024)
- kr509.0M
- Net income (Q2, 2024)
- (kr47.5M)
- Cash (Q2, 2024)
- kr797.3M
- EBIT (Q2, 2024)
- (kr31.5M)
- Enterprise value
- $11.4B